Reports Q4 revenue $24.56B, consensus $24.16B. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and CEO, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. In each of these important areas, our leadership is expanding driven by game-changing science and technology.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson (JNJ) Earnings Arrive as Talc Lawsuits Move Toward Trial
- Notable companies reporting before tomorrow’s open
- 4 Things Investors Are Watching as Markets Reopen After the Long Weekend
- Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?
- Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk